{"denoms":[{"counts":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"38"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"79"},{"groupId":"BG007","value":"64"},{"groupId":"BG008","value":"24"},{"groupId":"BG009","value":"570"}],"units":"Participants"}],"groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"BG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"BG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"BG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"BG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"BG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"BG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in AP CML who were IM R/I or multiple tyrosine kinase inhibitor (Multi-TKI): IM, D and/or NI R/I.","id":"BG006","title":"AP-CML Total (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in blast phase (BP) CML who were IM R/I or Multi-TKI: IM, D and/or NI R/I.","id":"BG007","title":"BP-CML Total (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"BG008","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"},{"description":"Total of all reporting groups","id":"BG009","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}],"title":"<18 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"29"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"179"}]}],"title":"Between 18 and 44 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"45"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"272"}]}],"title":"Between 45 and 64 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"119"}]}],"title":">=65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"35"},{"groupId":"BG007","value":"22"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"270"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"44"},{"groupId":"BG007","value":"42"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"300"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"All-treated population - included all enrolled participants who received at least one dose of bosutinib."}